SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement
File(s)
Accepted version
Accepted version
Author(s)
Alexander, James
Hart, Ailsa
Segal, Jonathan P
Powell, Nicholas
Type
Journal Article
Abstract
SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide the best opportunity for controlling transmission and protecting populations. Despite the impressive clinical trial results of the BNT162b2 (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and mRNA-1273 (Moderna) vaccines, important unanswered questions remain, especially in patients with pre-existing conditions. In this position statement endorsed by the British Society of Gastroenterology Inflammatory Bowel Disease (IBD) section and IBD Clinical Research Group, we consider SARS-CoV-2 vaccination strategy in patients with IBD. The risks of SARS-CoV-2 vaccination are anticipated to be very low, and we strongly support SARS-CoV-2 vaccination in patients with IBD. Based on data from previous studies with other vaccines, there are conceptual concerns that protective immune responses to SARS-CoV-2 vaccination may be diminished in some patients with IBD, such as those taking anti-TNF drugs. However, the benefits of vaccination, even in patients treated with anti-TNF drugs, are likely to outweigh these theoretical concerns. Key areas for further research are discussed, including vaccine hesitancy and its effect in the IBD community, the effect of immunosuppression on vaccine efficacy, and the search for predictive biomarkers of vaccine success.
Date Issued
2021-03-01
Date Acceptance
2021-01-13
Citation
The Lancet Gastroenterology and Hepatology, 2021, 6 (3), pp.218-224
ISSN
2468-1253
Publisher
Elsevier
Start Page
218
End Page
224
Journal / Book Title
The Lancet Gastroenterology and Hepatology
Volume
6
Issue
3
Copyright Statement
© 2021 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor
Crohn's & Colitis UK
Imperial College Healthcare NHS Trust- BRC Funding
Grant Number
M2019/2 Powell
RDA27
Subjects
Science & Technology
Life Sciences & Biomedicine
Gastroenterology & Hepatology
INFLUENZA VACCINE
IMMUNE-RESPONSES
CROHNS-DISEASE
IMMUNOSUPPRESSION
CHILDREN
THERAPY
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
COVID-19
COVID-19 Vaccines
ChAdOx1 nCoV-19
Disease Transmission, Infectious
Gastroenterology
Humans
Immunocompromised Host
Inflammatory Bowel Diseases
SARS-CoV-2
Societies, Medical
United Kingdom
Vaccination
Inflammatory Bowel Disease section of the British Society of Gastroenterology and the the Inflammatory Bowel Disease Clinical Research Group
Humans
Inflammatory Bowel Diseases
Vaccination
Gastroenterology
Immunocompromised Host
Societies, Medical
Disease Transmission, Infectious
United Kingdom
COVID-19
SARS-CoV-2
COVID-19 Vaccines
BNT162 Vaccine
2019-nCoV Vaccine mRNA-1273
ChAdOx1 nCoV-19
Publication Status
Published
Date Publish Online
2021-01-26